Leadership
|
Irene M. Ghobrial, MD
Attending Physician, Medical Oncology, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School Director, Clinical Investigator Research Program, Dana-Farber Cancer Institute Director, Michele & Stephen Kirsch Laboratory Co-Director, Center for the Prevention of Progression of Blood Cancers (CPOP) Co-Director, Blood Cancer Research Partnership (BCRP) education Hematology, Mayo Clinic Graduate Medical Education, 2004. Oncology, Mayo Clinic Graduate Medical Education, 2004. Internal Medicine, Sinai-Grace Hospital of Detroit, 2001. MD, Cairo University School of Medicine, 1995. contact info Irene_Ghobrial@dfci.harvard.edu LinkedIn | Twitter: @IreneGhobrial Facebook: Irene Ghobrial, MD | YouTube |
Dr. Ghobrial is a physician scientist who specializes in the field of Multiple Myeloma (MM) and Waldenström Macroglobulinemia (WM), specifically in the precursor conditions of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering disease.
Dr. Ghobrial's lab focuses particularly on understanding how early precursor conditions like MGUS/smoldering MM progress to overt MM. We examine genetic, epigenetic, and immune alterations that regulate tumor dissemination and the role of the bone marrow niche in disease progression from early precursor stages (MGUS and SMM) to active Multiple Myeloma. We aim to understanding of the biological changes that occur during progression in MM and develop therapeutic strategies to .
In addition, her laboratory research data has been rapidly translated to innovative investigator-initiated clinical trials. They have conducted over 10 phase I and II clinical trials. Their studies on MM cell trafficking have been translated to the first chemosensitization trials in patients with Multiple Myeloma.
Dr. Ghobrial is the co-leader of the Blood Cancer Research Partnership (BCRP), the first consortium of clinical trials for blood cancers in collaboration with the Leukemia and Lymphoma Society. The BCRP is a consortium of community oncology sites coordinated by Dana-Farber Cancer Institute to bring innovative clinical trials to more patients.
Moreover, she initiated the Center for Prevention of Progression of Blood Cancers (CPOP) where patients with precursor conditions such as MGUS, early Myelodysplastic Syndrome (MDS) and early Chronic Lymphocytic Leukemia (CLL) will be monitored prospectively for clonal evolution during disease progression. The PROMISE study, which screens health people who may be at risk for precursor conditions, and the PCROWD study, a tissue bank study collecting samples from patients with precursor conditions, are part of this effort. Clinical trials and research efforts are being coordinated for patients with these conditions to develop therapeutic agents that can prevent/delay disease progression in these early malignant conditions.
Dr. Ghobrial's lab focuses particularly on understanding how early precursor conditions like MGUS/smoldering MM progress to overt MM. We examine genetic, epigenetic, and immune alterations that regulate tumor dissemination and the role of the bone marrow niche in disease progression from early precursor stages (MGUS and SMM) to active Multiple Myeloma. We aim to understanding of the biological changes that occur during progression in MM and develop therapeutic strategies to .
In addition, her laboratory research data has been rapidly translated to innovative investigator-initiated clinical trials. They have conducted over 10 phase I and II clinical trials. Their studies on MM cell trafficking have been translated to the first chemosensitization trials in patients with Multiple Myeloma.
Dr. Ghobrial is the co-leader of the Blood Cancer Research Partnership (BCRP), the first consortium of clinical trials for blood cancers in collaboration with the Leukemia and Lymphoma Society. The BCRP is a consortium of community oncology sites coordinated by Dana-Farber Cancer Institute to bring innovative clinical trials to more patients.
Moreover, she initiated the Center for Prevention of Progression of Blood Cancers (CPOP) where patients with precursor conditions such as MGUS, early Myelodysplastic Syndrome (MDS) and early Chronic Lymphocytic Leukemia (CLL) will be monitored prospectively for clonal evolution during disease progression. The PROMISE study, which screens health people who may be at risk for precursor conditions, and the PCROWD study, a tissue bank study collecting samples from patients with precursor conditions, are part of this effort. Clinical trials and research efforts are being coordinated for patients with these conditions to develop therapeutic agents that can prevent/delay disease progression in these early malignant conditions.